Vaccines and diagnostic methods for bovine mastitis: fact and fiction.
A number of problems are uniquely associated with vaccination of dairy cows for mastitis. One of these is that the number of mastitis pathogens is numerous and heterogeneous. Vaccine efforts have concentrated mainly on the major mastitis pathogens. While at least one S. aureus bacterin has been commercially available for a number of years, no large-scale, independent field trials have been published in refereed journals which support the efficacy of this vaccine. Experimental vaccines for S. aureus composed of pseudocapsule-enriched bacterins supplemented with alpha- and/or beta-toxoids appear promising, but none of these has been commercialized. With S. uberis, some protection against homologous strain challenges was reported recently with a live strain and a bacterin, but other data from the same laboratory showed this vaccine would not protect against heterologous challenge strains. At this time there is only one highly effective vaccine for mastitis, the core-antigen vaccine for coliform mastitis. All of the commercially available vaccines for this indication are bacterins of rough mutants of E. coli strain J5 or Salmonella spp. Preliminary success with an experimental vaccine based on the plasminogen activator of S. uberis is a very different approach for a mastitis vaccine. Little success has been reported with vaccination against other mastitis pathogens. For diagnostic methods, the high somatic cell count, as measured by direct count or indirect assays, remains the cornerstone of mastitis diagnosis. However, for subclinical mastitis, bacterial cell culture is a reliable diagnostic method. Pathogen identification may rely on older biochemical testing methods or newer commercial identification systems, depending on the laboratory budget. ELISA assays also have been used to assess herd infection status. Epidemiologic studies have used DNA fingerprinting and ribotyping, but none of these methods has yet produced an easily utilized commercial format. Within the next decade, additional efficacious vaccines for several of the most common agents for bovine mastitis are likely. A review written at that time then can be more fact than fiction.
Yancey
R J
RJ
Pfizer Central Research, Groton, Connecticut 06340, USA.
D000818:Animals; D001428:Bacterial Vaccines; D002417:Cattle; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000276:immunology / Q000662:veterinary; D005260:Female; D008414:Mastitis, Bovine / Q000175:diagnosis* / Q000276:immunology* / Q000517:prevention & control; D012481:Salmonella Infections, Animal / Q000175:diagnosis / Q000276:immunology; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000276:immunology / Q000662:veterinary; D013211:Staphylococcus aureus; D013290:Streptococcal Infections / Q000175:diagnosis / Q000276:immunology / Q000662:veterinary; D013292:Streptococcus agalactiae
D001428:Bacterial Vaccines